Biopsy Devices Market Size & Growth Forecast 2027–2036, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Biopsy Devices Market size was worth USD 2.7 billion in 2026 and is expected to grow at a 6.84% CAGR between 2027 and 2036, reaching USD 5.23 billion by 2036. The industry revenue for 2027 is estimated at USD 2.86 billion.
Get more details on this report
Request Free Sample ReportBiopsy Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 45.69% share due to high procedural volumes, strong cancer screening programs, established image-guided biopsy pathways, and advanced hospital infrastructure.
- Asia Pacific is expanding at 8.25% CAGR as diagnostic utilization rises, minimally invasive procedures expand, and healthcare systems increase access to image-supported biopsy techniques.
Segment Momentum
- Needle-based Biopsy Guns held a 45.69% market share in 2026 due to their reliable specimen collection, operator control, clinical familiarity, and compatibility with routine biopsy workflows across healthcare settings.
- Biopsy Needles are the fastest-growing segment because they support procedure-specific sampling across different tissues and anatomical sites, aligning with growing demand for more targeted and customized biopsy procedures.
Market Expansion Drivers
- Rising global cancer incidence increasing demand for accurate tissue diagnostic procedures.
- Growing preference for minimally invasive biopsies accelerating innovation in precision biopsy technologies.
- Expanding healthcare infrastructure in emerging economies improving access to cancer diagnostics.
Leading Market Participants
- Major companies in the biopsy devices market include Hologic, Inc. (United States), Danaher Corporation (United States), Cardinal Health, Inc. (United States), Cook Medical LLC (United States), CONMED Corporation (United States), Devicor Medical Products, Inc. (United States), Becton, Dickinson and Company (United States), Argon Medical Devices, Inc. (United States), INRAD, Inc. (United States), Fujifilm Holdings Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.7 billion
- 2027 Estimated Market Size: USD 2.86 billion.
- Projected Market Size: USD 5.23 billion by 2036
- Growth Forecast: 6.84% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Needle-based Biopsy Guns (Product)
- Emerging Opportunity Segment: Biopsy Needles (Product)
Market Growth Drivers and Industry Trends
Rising global cancer incidence increasing demand for accurate tissue diagnostic procedures
Rising cancer incidence is driving the biopsy devices market as accurate tissue sampling remains essential for confirming diagnoses and determining appropriate treatment strategies. Biopsy procedures allow healthcare professionals to obtain tissue or cellular samples for pathological and molecular assessment, supporting differentiation between malignant and non-malignant conditions. As the need for timely and reliable cancer diagnosis expands, healthcare providers require biopsy devices capable of obtaining representative samples while supporting consistent procedural performance.
Growing preference for minimally invasive biopsies accelerating innovation in precision biopsy technologies
The biopsy devices market is gaining from the increasing preference for minimally invasive diagnostic procedures that can reduce patient discomfort, procedural complications, and recovery requirements. Advances in biopsy technology are enabling more precise tissue targeting through improved device designs and image-guided approaches, supporting accurate sampling from challenging anatomical locations. These developments are encouraging healthcare providers to adopt specialized devices that combine tissue acquisition with greater procedural control and patient convenience.
Expanding healthcare infrastructure in emerging economies improving access to cancer diagnostics
Expansion of healthcare infrastructure in emerging economies is creating new opportunities for the biopsy devices market by increasing access to diagnostic services and specialized medical procedures. Investments in hospitals, diagnostic centers, imaging capabilities, and pathology services can improve the availability of tissue sampling for patients who previously had limited access to cancer diagnostics. As healthcare systems strengthen their diagnostic capacity, demand for biopsy equipment is increasing alongside the broader availability of cancer screening and confirmatory testing.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer incidence increasing demand for accurate tissue diagnostic procedures | 1.90% | High | North America, Asia Pacific | High | Near Term |
| Growing preference for minimally invasive biopsies accelerating innovation in precision biopsy technologies | 1.70% | Moderate | North America, Europe | High | Mid Term |
| Expanding healthcare infrastructure in emerging economies improving access to cancer diagnostics | 1.40% | Moderate | Asia Pacific, Latin America | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The biopsy devices market was led by North America, which accounted for a 45.69% share in 2026, reflecting the region's advanced healthcare infrastructure, high adoption of minimally invasive diagnostic procedures, and strong focus on early disease detection. Well-developed oncology and diagnostic care networks support consistent utilization of tissue sampling technologies across hospitals and specialized facilities. The increasing integration of image-guided procedures and sophisticated diagnostic workflows is encouraging demand for devices that improve sampling accuracy, procedural efficiency, and patient outcomes. Strong clinical expertise and continued investment in healthcare technology further reinforce the region's established position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing market, benefiting from expanding healthcare infrastructure, improving access to diagnostic services, and growing awareness of early detection and cancer screening. Rising healthcare expenditure and the development of specialized hospitals are increasing the availability of biopsy procedures beyond major urban centers. At the same time, greater adoption of minimally invasive techniques is encouraging healthcare providers to incorporate advanced biopsy devices into diagnostic pathways. Improvements in medical training, imaging capabilities, and clinical capacity are also helping expand the use of tissue sampling technologies across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Imaging IntegrationGermany emphasizes the integration of biopsy devices with advanced imaging systems to strengthen diagnostic precision in hospitals and specialized care centers. Manufacturers focus on reliable instrument performance and workflow efficiency to support evolving clinical practice requirements.
France 🇫🇷
Oncology Care SupportFrance focuses on strengthening biopsy device adoption within oncology and specialized diagnostic services where accurate tissue collection remains essential. Healthcare providers increasingly standardize advanced biopsy procedures to improve patient management and laboratory efficiency.
Italy 🇮🇹
Hospital Procedure OptimizationItaly supports broader adoption of biopsy devices through hospital modernization and improved access to minimally invasive diagnostic procedures. Clinical teams continue selecting technologies that streamline workflows while enhancing diagnostic confidence across multiple medical specialties.
Japan 🇯🇵
Minimally Invasive CareJapan prioritizes minimally invasive biopsy procedures that align with patient-centered healthcare and early disease detection initiatives. Medical institutions increasingly adopt precision biopsy devices that enhance procedural consistency and support improved diagnostic outcomes.
South Korea 🇰🇷
Technology-Enabled DiagnosticsSouth Korea continues expanding the use of advanced biopsy devices through investments in digital healthcare infrastructure and modern diagnostic capabilities. Hospitals increasingly integrate image-guided technologies that improve procedural efficiency and support accurate tissue sampling.
United States 🇺🇸
Precision Diagnostics AdoptionThe U.S. biopsy devices market is driven by growing use of image-guided and minimally invasive diagnostic procedures across oncology and specialty care. Healthcare providers continue investing in advanced biopsy technologies that improve diagnostic accuracy while supporting efficient clinical workflows.
Segment Leadership and Growth Trends
Biopsy Devices Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Needle-based Biopsy Guns (Largest Segment) vs Biopsy Needles (Fastest-Growing Segment)
Needle-based biopsy guns held the largest share of the biopsy devices market in 2026, accounting for 45.69% share, supported by their ability to obtain tissue samples efficiently and consistently during minimally invasive diagnostic procedures. Their controlled sampling mechanism can improve procedural precision while reducing the need for more invasive approaches. Increasing adoption of image-guided biopsies and growing emphasis on accurate tissue diagnosis are supporting demand for biopsy guns across clinical settings.
Biopsy needles represent the fastest-growing segment, driven by the expanding use of minimally invasive tissue sampling across a broad range of diagnostic procedures. Advances in needle design are supporting improved targeting, sample quality, and procedural flexibility, particularly as clinicians increasingly seek less invasive diagnostic options. Growing demand for early disease detection and image-guided interventions is further strengthening the role of biopsy needles in modern diagnostic workflows.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Needle-based Biopsy Guns, Biopsy Guidance Systems, Biopsy Needles, Biopsy Forceps, Others | Needle-based Biopsy Guns | Biopsy Needles |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the biopsy devices market:
1. Hologic Inc. (United States)
2. Danaher Corporation (United States)
3. Cardinal Health Inc. (United States)
4. Cook Medical LLC (United States)
5. CONMED Corporation (United States)
6. Devicor Medical Products Inc. (United States)
7. Becton Dickinson and Company (United States)
8. Argon Medical Devices Inc. (United States)
9. INRAD Inc. (United States)
10. Fujifilm Holdings Corporation (Japan)
The biopsy devices market is advancing through improved diagnostic precision and minimally invasive technologies. Innovation is enhancing sampling accuracy and procedural efficiency. Continuous development is supporting better clinical outcomes. Growing demand for early diagnosis is strengthening device adoption.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Hologic Inc. (United States) | |||||||
| Danaher Corporation (United States) | |||||||
| Cardinal Health Inc. (United States) | |||||||
| Cook Medical LLC (United States) | |||||||
| CONMED Corporation (United States) | |||||||
| Devicor Medical Products Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Argon Medical Devices Inc. (United States) | |||||||
| INRAD Inc. (United States) | |||||||
| Fujifilm Holdings Corporation (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Halma plc | Nov-24 | Halma plc completed a £42 million acquisition of Lamidey Noury Medical, a French manufacturer of advanced electrosurgical devices. This strategic move expands Halma's healthcare portfolio into minimally invasive surgical and diagnostic energy technologies, providing adjacent capabilities that complement its existing presence in the biopsy and medical device markets. |
| Mammotome | Nov-24 | Mammotome, a subsidiary of Devicor, launched the AutoCore biopsy system, designed for breast tissue examinations. The device introduces automated spring-loaded capabilities that improve upon traditional core needle instruments, enhancing procedural efficiency for healthcare providers and reducing the time required to obtain high-quality tissue samples during biopsies. |
| Single Pass | Apr-24 | Single Pass received FDA clearance for its Kronos biopsy closure device, a Class II medical device. The system utilizes electrocautery to facilitate tract closure and hemostasis following percutaneous solid organ biopsies, addressing a critical need to minimize post-procedural bleeding complications in high-risk biopsy applications such as kidney and lung sampling. |
| Mammotome | Aug-23 | Mammotome launched the HydroMARK Plus Breast Biopsy Site Marker, a diagnostic accessory designed to improve the accuracy of tissue marking. By mitigating the risk of marker displacement, this technology enhances post-biopsy visualization and patient monitoring, representing a meaningful innovation in clinical biopsy workflows and diagnostic follow-up. |
| Argon Medical Devices | May-23 | Argon Medical Devices introduced the SuperCore Advantage semi-automatic biopsy instrument for soft tissue applications. The device features increased spring strength and an integrated coaxial adapter to maximize sample yield, effectively reducing the number of needle passes required during diagnostic procedures and improving clinical efficiency for a variety of tissue sampling tasks. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Biopsy Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Procedure Setting | Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Specialty Clinics |
| Target Tissue Type | Breast, Lung, Liver, Prostate, Gastrointestinal, Other Tissues |
| End User | Hospitals & Academic Medical Centers, Diagnostic & Pathology Laboratories, Specialty Clinics, Ambulatory Surgical Centers |
Biopsy Devices Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Hospital Procurement and Purchasing Behavior Analysis |
|
| Minimally Invasive Diagnostics Adoption Outlook |
|
| Cancer Screening Program Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much is the biopsy devices market worth?
What is the expected industry size of biopsy devices by 2036?
How is rising cancer incidence influencing demand and procurement behavior in biopsy devices market?
How is minimally invasive biopsy adoption shaping technology innovation in the biopsy devices market?
Why are Needle-based Biopsy Guns the largest product segment in the biopsy devices market?
What is driving the growth of Biopsy Needles in the biopsy devices market?
Why does North America dominate the biopsy devices market?
What is supporting growth in Asia Pacific biopsy devices market?
What are the key competitors in the biopsy devices landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization